A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Clinical trial NCT04622046 · COMPLETED

Trial details

NCT number: NCT04622046
Sponsor: Alexion Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Symptomatic Transthyretin Amyloid Cardiomyopathy

Start date: 2020-11-13
Primary completion: 2023-11-08
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.